Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing novel treatments for gastrointestinal, or GI, diseases.
The company’s approved products, VOQUEZNA, VOQUEZNA DUAL PAK, and VOQUEZNA TRIPLE PAK, cont…
Analysis
Middle-of-the-road
Phathom Pharmaceuticals, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.
Valuation data is not available for this company.
The trajectory is solid and the balance sheet is stretched. The company scores 7/20 on our value-creation score: creating some value.
Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Mar 202634
58
2026
All-time high
58
Jun 2026
All-time low
34
Mar 2026
Average rank
46
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
75
—
—
—
Price/Earnings
12
—
—
—
Price/Book
86
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
66
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.